The Straumann Group increases stake in French implant manufacturer Anthogyr from 30% to full ownership

The Straumann Group and its partner Anthogyr have signed an agreement that paves the way for Straumann to increase its stake in Anthogyr from 30% to full ownership.

The transaction is expected to close early in the second quarter. Financial details were not disclosed.

With a history of almost 30 years in implantology, Anthogyr is a well-established brand that develops, manufactures and sells innovative, implant and CADCAM solutions.

Its comprehensive portfolio addresses the upper value implant segment and includes fully and apically tapered designs, as well as parallel-walled tissue and bone level implants.

The company has a strong clinical network of key opinion leaders in its home market, where it is the largest supplier of non-premium implant solutions.

The partnership between the two companies dates back to early 2016, when Straumann acquired a 30% stake and took over Anthogyr’s business in China.

Marco Gadola, CEO of the Straumann Group said: ‘Our companies are a good cultural fit and our partnership over the past three years has been very successful.

‘Anthogyr provided us with timely footholds in the non-premium implant segments in China and Russia, where we have been able to generate strong growth with the brand.

‘Our goal is to drive its international expansion together with Neodent, Medentika and our other brands, offering customers and their patients high-quality implant solutions with a broader range of price options than other companies can offer.’

Eric Genève, president and CEO of Anthogyr commented: ‘Straumann provides us with the global platform and resources we need to expand internationally.

‘We are immensely proud of our union with the world’s leading implant company and are convinced that it will add value for our staff, customers and patients.’

For more information see www.straumann-group.com